Insmed reported $2.26B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Cytokinetics USD 1.42B 12.02M Dec/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025